The FDA has cleared EndeavorRxTM (AKL-T01; Akili Interactive) for use as a prescription-only video game-based digital therapeutic to improve attention function in pediatric patients aged 8-12 years with primarily inattentive or combined-type ADHD.
For children with ADHD, parents reported worsened ADHD behaviors during the COVID-19 outbreak, with children’s and parents’ moods positively associated with behavior.
Driven by the No Child Left Behind Act of 2001, school districts responded to pressures to increase school rankings and test scores by having more children tested for ADHD.
The investigators observed a statistically significant relapse rate among those discontinuing medication for ADHD, which remained significant in subgroup analyses of both age groups.
Healthcare utilization and expenditures on psychiatric and somatic disorders at 18 years were significantly higher in patients with a childhood diagnosis of ADHD for most outcomes.
Levels of greenness were determined through the normalized difference and soil-adjusted vegetation indices. The study was completed between April 2012 and January 2013.
The effect of omega-3 fish oil supplements on cognitive symptoms in children and adolescents with attention-deficit/hyperactivity disorder (ADHD) may vary according to endogenous levels of eicosapentaenoic acid (EPA).
Maternal paracetamol use during 18 to 32 weeks of gestation is associated with a higher risk for attention problems and hyperactivity in children 42 to 47 months of age.
ADHD medication use was associated with a lower risk for emergency department visits for unintentional injuries and traumatic brain injuries in both boys and girls at the population and individual levels.
Although the number of young people with attention-deficit/hyperactivity disorder (ADHD) who are treated with antipsychotic drugs is low, many antipsychotic prescriptions do not appear to be clinically warranted.
